Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India

Pediatric Infectious Disease Journal

Volumn 26, Issue 11, 2007, Pages 1038-1041

  Velu, Vijayakumar ^a   Nandakumar, Subhadra ^a   Shanmugam, Saravanan ^a,b   Shankar, Esaki Muthu ^a,b   Thangavel, Sundararajan ^a   Kulkarni, Prasad Suryakant ^c   Thyagarajan, Sadras Panchatcharam ^a,b,d,e  

^a UNIVERSITY OF MADRAS   (India)

^b VHS Medical Centre India   (India)

^c Serum Institute of India Ltd   (India)

^d SRI RAMACHANDRA UNIVERSITY   (India)

^e YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

Adolescent vaccination; GeneVac B; Hepatitis B vaccine; Immunogenicity

Indexed keywords

GENVAC B; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; NORMAL HUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT;

EID: 37349118283     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181342887     Document Type: Article

References (34)

1. Kane MA, Clements J. In: Jamison DT, Mosley WH, Meashan AR, Bobadilla J, eds. Hepatits B in Disease Control Priorities in Developing Countries. New York, NY: World Bank Book, Oxford University Press; 1993;321-330.
2. Park K. Textbook of Prevention and Social Medicine. 15th ed. Jabalpur, India: M/S Banarsidas Bhanot Publishers; 1997:159.
3. Thyagarajan SP, Jayaram S, Mohanavalli B. Prevalence of HBV in general population in India. In: Sarin SK, Singal AK, eds. Hepatitis B in India: Problems and Prevention. New Delhi, India: CBS Publishers; 1996:5-16.
4. Margolis HS. Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. J Infect Dis. 1993;168:9-14.
5. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:196-204.
6. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40:1-25.
7. American Academy of pediatrics committee on infectious disease. Universal hepatitis B immunization. Pediatrics. 1991;89:795-800.
8. Hyams KC. Risk of chronicity following acute hepatitis B virus infection. A review. Clin Infect Dis. 1995;20:992-1000.
9. Slevens CE, Beasley RP, Jsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1995;292:771-774.
10. Hyams KC, Osman NM, Khaled EM, et al. Maternal-infant transmission of hepatitis B in Egypt. J Med Virol. 1998;24:191-197.
11. Basalamah AH, Serebour F, Kazem E. Materno-foetal transmission of hepatitis B in Saudi Arabia. J infect. 1984;8:200-204.
12. Botha JF, Dushecbo GM, Ritchie MJJ, Mouton HWK, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet. 1984;1:1210-1212.
13. Hsu H-M, Lu-F, Lee S-C, Lin S-R, Chen D-S. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass vaccination. J Infect Dis. 1999;179:367-370.
14. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855-1859.
15. American Academy of Pediatrics. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997.
16. World Health Organization. Report of the World Health Organization working group on Hepatitis B. Western Pacific Region, Seoul, Korea. August 24-26, 1987.
17. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolec Health. 1995;16:12-17.
18. Halsey NA, Moulton LH, Donovan CO, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999;103:1243-1247.
19. Duval B, Boulianne N, De Serres, et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10 year-old children. Vaccine. 2000;18:1467-1462.
20. Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two-and three-dose Hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics. 2001;107:626-631.
21. Guptan RC, Thakur V, Safary A, Sarin SK. Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children. Vaccine. 2002;20:2102-2106.
22. Levie K, Beran J, Collard F, Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine. 2002;20:2579-2584.
23. Kulkarni PS, Raul SK, Patki PS, et al. Immonogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine. 2006;24:3457-3460.
24. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986;13:39-45.
25. West DJ, Calandra GB, Ellis RW. Vaccination of infants and children against hepatitis B. Pediatr Clin North Am. 1990;37:585-601.
26. Goh KT, Tan KL, Kong KH, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast recombinant hepatitis B vaccine in Singapore children: a four year follow-up study. Bull World Health Organ. 1992;70:233-239.
27. Kakrani AL, Bharadwaj R, Karmarkar A, et al. Immune responses induced by two dose strengths of a yeast-derived recombinant hepatitis B vaccine in adolescents. Indian J Gastroenterol. 2003;22:71-72.
28. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimens for adolescents: two doses 12 months apart. Vaccine. 2002;20:3472-3476.
29. Chen C-C, Chang M-H, Lee H-C, Twu S-J, Safary A. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Acta Paediatr Taiwan. 1999;40:157-160.
30. Poovorawan Y, Pongpunlert W, Theamboonlers A, et al. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 microgram and 10 microgram doses of hepatitis B vaccine in adolescents. Southeast Asian J Trop Med Public Health. 1993;24:255-259.
31. Andre FE, Path FRC. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. Am J Med. 1989;87:14-20.
32. Burgess MA, Rodger AJ, Waite SA, Collard F. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine. 2001;19:4835-4841.
33. Vijayakumar V, Shraddha M, Subhadra N, Saravanan S, Sundararajan T, Thyagarajan SP. Immunogenicity and safety of 10 mg and 20 mg doses of GeneVac-B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J Gastroenterol. 2004;23:34-35.
34. Vijayakumar V, Hari R, Parthiban R, Mehta J, Thyagarajan SP. Evaluation of immunogenicity and safety of GeneVac-B: a new recombinant hepatitis B vaccine in comparison with Engerix B and Shanvac B in healthy adults. Ind J Med Microbiol. 2004;22:34-38.